| Biomarker ID | 963 |
| PMID | 22821756 |
| Year | 2012 |
| Biomarker | PCA3 + phi |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Urine + Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | PCa Vs No-PCa |
| Type of Biomarker | Diagnostic |
| Cohort | 160 patients were included in the study, ouut of which 113 did not have prostate cancer and 47 had prostate cancer. |
| Senstivity | 0.70 (95% CI: 0.57–0.83) |
| Specificity | 0.76 (95% CI: 0.67–0.83) |
| AUC | 0.77 (95% CI: 0.69–0.85) |
| Accuracy | NA |
| Level Of Significance | p=0.001 |
| Method Used | NA |
| Clinical | No |
| Remarks | The PCA3 score was calculated as mRNA PCA3/mRNA PSA x 1000 |
| Clinical Trial Number | NA |
| Degree Of Validity | not validated on independent patient dataset |
| Technical Name | NA |